Treatment

Results from the phase 3 ELEVATE trial show that ensartinib (Ensacove) significantly reduced the risk of cancer recurrence in patients with completely resected stage IB to IIIB ALK-positive non-small cell lung cancer (NSCLC) after chemotherapy. Among patients with stage II to IIIB disease, the 24-month disease-free survival (DFS) rate was 86.4% with ensartinib, compared with […]

The oral drug INCB123667 showed encouraging early results in patients with platinum-resistant ovarian cancer whose tumors overexpress cyclin E1, a protein linked to poor outcomes. In a Phase 1 trial, 14 patients receiving a 100-mg daily dose achieved an overall response rate of 35.7%, with all responses being partial. The disease control rate was 71.4%,

Updated results from the CIRCULATE-Japan GALAXY study show that a blood test for circulating tumor DNA (ctDNA) can help identify which patients benefit from chemotherapy after surgery for colorectal cancer liver metastases. Among patients who had surgery first, those with detectable ctDNA after surgery gained major benefits from adjuvant chemotherapy. Their four-year overall survival rate

A retrospective analysis from the phase 3 ATOMIC trial suggests that patients with stage III dMMR colon cancer may benefit most from adding Atezolizumab to standard FOLFOX chemotherapy when they are able to complete more than six cycles of treatment. Patients who received more than six cycles of FOLFOX plus atezolizumab had a significantly lower

Results from the phase 2 eNRGy trial, published in the Journal of Clinical Oncology, supported the FDA approval of Zenocutuzumab as a second-line treatment for patients with advanced NRG1-positive Cholangiocarcinoma. The study included 22 patients whose cancer had progressed after previous treatment. Zenocutuzumab achieved an objective response rate of 36.8%, compared with about 5% historically

Botensilimab plus balstilimab showed encouraging long-term results in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases, according to three-year follow-up from the phase 1b C-800-01 trial. Among 123 patients, median overall survival reached 21.2 months, nearly double the historical 10–14 months seen with standard later-line treatments. The objective response rate

New clinical trial results presented at the 2026 ESMO GI Cancers Congress suggest that zoldonrasib-based treatments may significantly improve outcomes for patients with KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC). In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82% and a disease control rate of 96%. When combined

The phase 3 MANGROVE trial showed that a chemotherapy-free combination of zanubrutinib (Brukinsa) and rituximab (Rituxan) significantly improved progression-free survival compared with standard chemoimmunotherapy as a first-line treatment for mantle cell lymphoma (MCL). The combination reduced the risk of disease progression or death by 43%. Overall survival data are still early but currently favor the zanubrutinib group.

The first planned interim analysis of the phase 2/3 MIRACLE trial showed that adding liposomal annamycin to high-dose cytarabine (HiDAC) produced higher remission rates than HiDAC alone in patients with relapsed or refractory acute myeloid leukemia (AML). After one treatment cycle, complete remission rates were 43% with the 190 mg/m² annamycin dose and 36% with the 230 mg/m² dose,

The phase 3 EPCORE DLBCL-4 trial found that a chemotherapy-free combination of epcoritamab (Epkinly) and lenalidomide (Revlimid) significantly improved progression-free survival compared with R-GemOx chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The treatment reduced the risk of disease progression or death by 56%–60%, depending on the analysis. No new safety concerns were identified,